We are live on ! Find out more
FCMI

Foresite Capital Management I Portfolio holdings

AUM $21.4M
1-Year Est. Return 80.48%
This Fund
S&P 500
This Quarter Est. Return
+16.51%
1 Year Est. Return
-80.48%
3 Year Est. Return
-40.72%
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$21.7M
AUM Growth
-$46.2M
Cap. Flow
-$48.9M
Cap. Flow %
-225.01%
Top 10 Hldgs %
100%
Holding
6
New
–
Increased
1
Reduced
3
Closed
2

Top Buys

Rank Stock Value
1
XLRN
Acceleron Pharma
XLRN
+$1.51M

Top Sells

Rank Stock Value
1
KPTI icon
Karyopharm Therapeutics
KPTI
+$37.4M
2
XNCR icon
Xencor
XNCR
+$9.35M
3
BDSI
BioDelivery Sciences International, Inc.
BDSI
+$2.41M
4
RXDX
Ignyta, Inc.
RXDX
+$1.22M
5
OREX
Orexigen Therapeutics, Inc.
OREX
+$35.4K

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
OREX
1
DELISTED
Orexigen Therapeutics, Inc.
OREX
$9.63M 44.28%
122,929
-571
-0.5% -$35.4K
BDSI
2
DELISTED
BioDelivery Sciences International, Inc.
BDSI
$5.19M 23.89%
494,468
-176,624
-26% -$2.41M
XLRN
3
DELISTED
Acceleron Pharma
XLRN
$3.57M 16.42%
93,781
+38,014
+68% +$1.51M
RXDX
4
DELISTED
Ignyta, Inc.
RXDX
$3.35M 15.42%
336,766
-163,234
-33% -$1.22M
KPTI icon
5
Karyopharm Therapeutics
KPTI
$216M
– –
-66,618
Closed -$37.4M
XNCR icon
6
Xencor
XNCR
$1.3B
– –
-582,881
Closed -$9.35M

Similar funds

A
Atlassian San Francisco, California $21M AUM 71.86% 1-Year Est. Return
CVGI
Craft Ventures GP II San Francisco, California $24.1M AUM 83.06% 1-Year Est. Return
AEPI
AH Equity Partners IV Menlo Park, California $24.5M AUM 73.4% 1-Year Est. Return
AGDR
AdamCapital Gestao de Recursos Rio De Janeiro, Brazil $18.1M AUM 32.38% 1-Year Est. Return
N
NanoDimension Woodside, California $24.7M AUM 74.01% 1-Year Est. Return
WL
WiL LLC Palo Alto, California $17.5M AUM 75.04% 1-Year Est. Return
NVPX
Norwest Venture Partners XIII Palo Alto, California $25.8M AUM 76.52% 1-Year Est. Return
SVGI
Sozo Ventures GP I Redwood City, California $16.3M AUM 66.18% 1-Year Est. Return

Foresite Capital Management I's Q1 2015 Portfolio in Review

As of Q1 2015, Foresite Capital Management I held 6 positions worth $21.7M, down 68% from $67.9M the previous quarter. Its ten largest holdings account for 100% of the portfolio.

Foresite Capital Management I withdrew a net $48.9M in Q1 2015, closing 2 positions and reducing 3 holdings. Its most notable exit was Karyopharm Therapeutics, an estimated $37.4M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.

Against the trend, Foresite Capital Management I added an estimated $1.51M to Acceleron Pharma.

  • Foresite Capital Management I added most to Acceleron Pharma in Q1 2015, an estimated $1.51M increase.
  • Foresite Capital Management I's biggest Q1 2015 reduction was BioDelivery Sciences International, Inc., cutting an estimated $2.41M.
  • Foresite Capital Management I fully exited Karyopharm Therapeutics in Q1 2015, selling an estimated $37.4M.
  • Foresite Capital Management I's ten largest holdings make up 100% of its $21.7M portfolio in Q1 2015.
  • Foresite Capital Management I opened 0 new positions and closed 2 in Q1 2015.
  • Foresite Capital Management I's portfolio value fell 68% quarter-over-quarter to $21.7M.

Based on Foresite Capital Management I's 13F filing for Q1 2015, filed 5 May 2015.